Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders for both hospital and home settings.
*Delayed quote courtesy of Google Finance.
View Stock Information
Lookup Date :
- Oct 17, 2019 Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting
- Sep 27, 2019 Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
View All Events